Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia

Pharmacological Reports

Volumn 59, Issue 2, 2007, Pages 181-191

  Bishnoi, Mahendra ^a   Chopra, Kanwaljit ^b   Kulkarni, Shrinivas K ^a,b  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Adenosine; Neuroleptic drugs; Tardive dyskinesia; Theophylline

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; CATALASE; DOPAMINE; DOPAMINE RECEPTOR; GLUTATHIONE; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTRANSMITTER; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THEOPHYLLINE; TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; LIPID PEROXIDATION; LOCOMOTION; MALE; MASTICATION; MAZE TEST; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; RAT; RECEPTOR SENSITIVITY; STEREOTYPY; TARDIVE DYSKINESIA; TONGUE;

EID: 34250737857     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Andia I, Zumarraga M, Retuerto F, Zamalloa I, Davila R: Chronic neuroleptic treatment does not suppress the dynamic characteristics of the dopaminergic receptor D2 system. Prog Neuropsychopharmacol Biol Psychiatry, 1994, 18, 181-191.
2. Bishnoi M, Chopra K, Kulkarni SK: Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioral, biochemical and neurochemical changes. Eur J Pharmacol. 2006, 552, 55-66.
3. Burger MBE, Alves A, Callegari L, Athayde FR, Zeni G: Ebselen attenuates reserpine-induced orofacial dyskmesia and oxidative stress in rat striatum. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 17, 135-140.
4. Burger MBE, Fachineto R, Alves A, Callegari L, Rocha JBT: Acute reserpine and sub-chronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res, 2005, 1031, 202-210.
5. Burger MBE, Fachineto R, Callegari L, Paixao MW, Braga AL, Rocha JBT: Effect of age on reserpine induced orofacial dyskinesia possible protection of diphenyl diselenide. Brain Res Bull, 2004, 64, 339-345.
6. Burger MBE, Fachineto R, Zeni G, Rocha JBT: Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacol Biochem Behav, 2005, 81, 608-615.
7. Casey DE: Tardive dyskinesia; pathophysiology and animal models. Indian J Psychiatry, 2000, 61, 5-9.
8. Chu CY, Liu YL, Chiu HC, Jee SH: Dopamine-induced apoptosis in human melanocytes involves generation of reactive oxygen species. Br J Dermatol, 2006, 154, 1071-1079.
9. Church WH: Column Chromatography analysis of brain tissue: an advanced laboratory exercise for neuroscience major. The Journal of Undergraduate Neuroscience Education, Spring, 2005, 3, A36-A41.
10. Croning MD, Zetterstrom TS, Grahame-Smith DG, Newberry NR: Action of adenosine receptor antagonists on hypoxia-induced effects in the rat hippocampus in vitro. Br J Pharmacol, 1995, 116, 2113-2119.
11. Ellman GL: Tissue sulfhydryl groups. Arch Biochem-Biophys, 1959, 82, 70-77.
12. Gerlach J, Casey DE: Tardive dyskinesia. Acta Psychiatr Scan, 1988, 77, 369-378.
13. Hyde JF, Jerussi TP: Bilateral neurochemical changes induced by unilateral cerebral haloperidol administration: evidence for cerebral asymmetry in the rat. Pharmacol Biochem Behav, 1992, 42, 457-464.
14. Hashimoto T, Ross DE, Gao XM, Medoff DR, Tamminga CA: Mixture in the distribution of haloperidol induced tardive dyskinesia in the rats supports an animal model of tardive dyskinesia. Psychopharmacology, 1998, 137, 107-112.
15. Hauber W, Bareib A: Facilitative effects of an adenosine A1/A2 receptor blockade on spatial memory performance of rats. Selective enhancement of reference memory retention during the light period. Behav Brain Res, 2001, 118, 43-52.
16. Itoh J, Nabeshima T, Kameyama T: Utility of an elevated plus maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol. 1994, 1991, 71-76.
17. Kane JM, Smith JM, Tardive dyskinesia: prevalence and risk factors. 1959-1979. Arch Gen Psychiatry, 1982, 39, 473-481.
18. Kono Y: Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dismutase. Arch Biochem Biophys, 1978, 186, 189-195.
19. Kulisevsky J, Barbanoj M, Gironell A, Antonijoan R, Casas M, Pascual-Sedano BA: Double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease. Clin Neuropharmacol, 2002, 25, 25-31.
20. Kulkarni SK: Handbook of Experimental Pharmacology, 3rd edn, Vallabh Prakashan, New Deli, 1999.
21. Lau YS, Mouradian MM: Protection against acute MPT-induced dopamine depletion in mice by adenosine. J Neurochem, 1993, 60, 768-771.
22. Listos J, Malec D, Fidecka S: Adenosine receptor antagonists intensify the benzodiazepine withdrawal signs in mice. Pharmacol Rep, 2006, 58, 643-651.
23. Lohr JB: Oxygen free radicals and neuropsychiatric illness. Arch Gen Psychiatry, 1991, 48, 1097-1106.
24. Lohr JB, Kuczenski R, Niculescu AB: Oxidative mechanisms and tardive dyskinesia. CNS Drugs, 2003, 17, 47-62.
25. Lowry OH, Rosenbrought NJ, Farr AL, Randall RJ: Protein measurements with the Folin-phenol reagent. J Biol Chem, 1951, 193, 265-275.
26. Luck H: Catalase spectrophotometric method In: Methods in Enzymatic Analysis. Ed. Bergmeyer HU, Academic Press, New York, 1963, 885-893.
27. Malec D, Poleszak E: Involvement of adenosine receptors in dizocilpine-induced motor activity in mice. Pharmacol Rep, 2006, 58, 101-106.
28. Mally J, Stone TW: The effect of theophylline on parkinsonian symptoms. J Pharm Pharmacol, 1994, 46, 515-517.
29. Mandryk M, Fidecka S, Poleszak E, Malic D: Participation of adenosine system in the ketamine-induced motor activity in mice. Pharmacol Rep, 2005, 57, 55-60.
30. Naidu PS, Kulkarni SK: Excitatory mechanisms in neuroleptics-induced vacuous chewing movements (VCM's): possible involvement of calcium and nitric oxide. Behav Pharmacol, 2001, 12, 209-216.
31. Naidu PS, Singh A, Kulkarni SK: Quercetin, a bioflatonoid attenuated haloperidol induced orofacial dyskinesia. Neuropharmacology, 2003, 44, 1100-1106.
32. Parsons B, Togasaki DM, Kassir S, Przedborski S: Neuroleptics upregulate adenosine A2A receptors in rat striatum: Implications for the mechanism and the treatment of tardive dyskinesia. J. Neurochem, 1995, 65, 2057-2064.
33. Reddy DS, Kulkarni SK: Possible role of nitric oxide in the nootropic and antiamnestic effects of neurosteroids on aging and dizocilpine induced learning impairment Brain Res, 1998, 799, 215-219.
34. Ribeiro JA, Sebastiao AM, Mendonca AD: Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol, 2003, 68, 377-392.
35. Schubert P, Ogata T, Marchini C, Ferroni S, Rudolph K: Protective mechanisms of adenosine in neurons and glial cells. Ann NY Acad Sci, 1997, 825, 1-10.
36. Stone TW: Adenosine, neurodegenaration and neuroprotection. Neurol Res, 2005, 27, 161-168.
37. Stone TW, Jones PA, Smith RA: Neuroprotection by A2A receptor antagonists. Drug Dev Res, 2001, 52, 323-330.
38. Tebano MT, Pintor A, Frank C, Domenici MR, Martire A, Pepponi R: Adenosine A2Areceptor blockade differentially influences excitotoxic mechanisms at pre- and postysnaptic sites in the rat striatum. J Neurosci Res, 2004, 77, 100-107.
39. Terland O, Almas B, Flatmark T, Andersson KK, Sorlie M: One-electron oxidation of catecholamines generates free radicals with an in vivo toxicity correlating with their lifetime. Free Radic Biol Med, 2006, 41, 1266-1271.
40. Tsai GC, Golf DC, Chang RW, Flood J, Baer L, Coyle JT: Markers of glutamatergic transmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry, 1998, 155, 1207-1213.
41. Wills ED: Mechanism of lipid peroxide formation in animal tissues. Biochem J, 1965, 99, 667-676.
42. Xu K, Bastia E, Schwarzschild M: Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol Ther, 2005, 105, 267-310.